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Background: Bone marrow-derived stem cells (BMSCs) are locally adjacent to the tumor tissues and may interact
with tumor cells directly. The purpose of this study was to explore the effects of BMSCs on the proliferation and
invasion of osteosarcoma cells in vitro and the possible mechanism involved.
Methods: BMSCs were co-cultured with osteosarcoma cells, and CCK-8 assay was used to measure cell proliferation.
The ELISA method was used to determine the concentration of stromal cell-derived factor-1 (SDF-1) in the supernatants.
Reverse transcription polymerase chain reaction (RT-PCR) was performed to detect the expression of CXCR4 in
osteosarcoma cells and BMSCs. Matrigel invasion assay was performed to measure tumor cell invasion.
Results: SDF-1 was detected in the supernatants of BMSCs, but not in osteosarcoma cells. Higher CXCR4 mRNA
levels were detected in the osteosarcoma cell lines compared to BMSCs. In addition, conditioned medium from
BMSCs can promote the proliferation and invasion of osteosarcoma cells, and AMD3100, an antagonist for
CXCR4, can significantly downregulate these growth-promoting effects.
Conclusions: BMSCs can promote the proliferation and invasion of osteosarcoma cells, which may involve the
SDF-1/CXCR4 axis.
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It has been increasingly recognized that cancer cells ac-
tively recruit stromal cells into tumors and this recruitment
is essential for the generation of a microenvironment that
promotes tumor growth [1]. Since the stroma cells can
stimulate tumor growth and invasiveness, stromal cells
play an active role in cancer progression, induce chemo-
therapy resistance, and inhibit cancer cell apoptosis [2-5].
Organs have abundant stroma surrounding them, and
tumor-stroma interactions play a critical role in tumor pro-
gression [6]. Although the exact mechanisms of tumor-
stroma interactions remain unclear, some chemokines,
including hepatocyte growth factor, epidermal growth
factor, vascular endothelial growth factor, and stromal
cell-derived factor-1 (SDF-1), have been shown to be
involved in the interaction [7,8].* Correspondence: yfxbmu@sina.com
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unless otherwise stated.SDF-1 belongs to the CXC chemokine family and is a
ligand for CXCR4. SDF-1 is expressed in stromal cells
[9], and CXCR4 expression has been found in many can-
cer types, including breast, ovary, kidney, prostate, and
stomach cancer tissue and cell lines [10-12]. In addition,
it has been demonstrated that the SDF-1/CXCR4 recep-
tor ligand system plays an important role in carcinoma
progression by promoting tumor cell migration and
angiogenesis [13,14].
The interactions between mesenchymal stem cells from
bone marrow and malignant tumors from the breast,
prostate, ovaries, and stomach have been recently de-
scribed [10,15]. Bone marrow-derived stem cells (BMSCs)
are locally adjacent to the tumor tissues and may interact
with tumor cells directly. However, the ability of BMSCs
to promote tumor cell proliferation remains controversial.
It has been reported that BMSCs can promote breast,
prostate, non-small lung, and glioblastoma cancer cell
growth in vivo [16-18]. In contrast, several reports have
shown an anti-tumor effect of mesenchymal stem cells.
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sarcoma xenotransplant [19]. Moreover, the co-implantation
of breast cancer cells with mesenchymal stem cells results in
tumor growth inhibition and a reduction of metastasis
in vivo [20]. However, the impact of BMSCs, which are a
type of local mesenchymal stem cell, on proliferation and in-
vasion of osteosarcoma has not been reported to date.
Therefore, in this study, we determined whether BMSCs
can promote the growth and invasion of osteosarcoma and
sought to explore the mechanism responsible for these ob-
served effects.Methods
Cell lines and reagents
Human osteosarcoma cell lines MG-63 and OS732 were
purchased from the Chinese Academy of Sciences (Shanghai,
China). Dulbecco’s modified Eagle’s medium (DMEM) and
fetal bovine serum (FBS) were provided by Gibco (Grand
Island, NY, USA), and recombinant human CXCL12
(SDF-1) was purchased from R&D systems (Minneapolis,
MN, USA). AMD3100, a chemokine receptor antagonist for
CXCR4, and Matrigel were obtained from Sigma-Aldrich
(St. Louis, MO, USA). The fluorochrome-conjugated anti-
bodies used for immunostaining - anti-CD45-APC, anti-
CD29-PE, and anti-CD90-FITC - and appropriate negative
controls were from BD (San Diego, CA, USA).Isolation of human BMSCs
Bone marrow was obtained from healthy persons who
had provided written informed consent. This process
was approved by the institutional review board of the
First Affiliated Hospital of Wenzhou Medical University.
A solution of density of 1.073 g/mL by dilution of Per-
coll was added to the bottom of the separating tube.
Then, the fresh bone marrow of 20 mL was added to
Percoll in a volume ratio of 1:1 gently. Centrifugation
was carried out at room temperature at 3,000 rpm for
30 min. The white cell band between the two layers was
transferred, and the pelleted cells were washed two times
with the medium without FBS. Finally, cells were resus-
pended and grown in low-glucose (1,000 mg/L) DMEM
(L-DMEM) containing 20% FBS, 100 μg/L penicillin, and
100 μg/L streptomycin in a humidified environment
with 5% CO2 at 37°C. After 48 h, unattached cells were
washed and removed. The cells were then grown in a
humidified incubator at 37°C for an additional 4 weeks.
Before phenotype analysis by flow cytometry, cells were
fixed and permeabilized by a Cytofix/Cytoperm reagent
(Becton Dickinson PharMingen, San Jose, CA, USA)
after being harvested from six-well assay plates. Then,
they were indicated by a panel of antibodies including
PE-conjugated CD29 antibody, FITC-conjugated CD90
antibody, and APC-conjugated CD45 antibody.Differentiation of human BMSCs into adipocytes
BMSCs were cultured to confluence in 35-mm dishes
containing DMEM. The medium was then removed and
fresh DMEM was added containing 0.5 mM IBMX,
1.0 μM dexamethasone, and 300 nM insulin. The cells
were cultured in the differentiation medium for 2 days,
and then the medium was changed every 2 days with
DMEM containing only 300 nM insulin for a total of
two times. After this step, the cells were incubated in
DMEM without any additives, which was changed every
10 days. Fully differentiated adipocytes were observed by
light microscopy based on morphology. Oil red O staining
was used to detect fat droplets for the various treatments
as described above.
Transwell co-culture system and CXCR4 antagonist
treatment
BMSCs were cultured in apical compartments of transwells
(transwell insert 0.4 μm; Millipore, Billerica, MD, USA)
with osteosarcoma cells grown in the basal compartment
of the plate (Millipore). BMSCs were seeded onto the
upper layer of transwells without direct contact with osteo-
sarcoma cells. Osteosarcoma cells were seeded onto the
lower layer of transwells. CXCR4 antagonist, AMD3100
(100 ng/mL), was added into the wells when drug experi-
ment was needed. All cells were grown in L-DMEM sup-
plemented with 10% FBS at 37°C in 5% CO2. As a control,
the same osteosarcoma cells were seeded instead of
BMSCs onto the upper layer. After culturing the cells
for 72 h, cell proliferation was analyzed using a CCK-8
kit (Dojindo, Kumamoto, Japan) following the manu-
facturer’s instructions.
Proliferation assay
The CCK-8 kit solution was added to each well, the cells
were incubated for another 2 h, and the absorbance at
450 nm was measured by using a spectrophotometer. The
amount of the formazan dye, generated by the activities of
dehydrogenases in cells, is directly proportional to the
number of living cells. The proliferation rate (%) of cells
was calculated using the following equation: 1 − (A of
control −A of BMSCs) / (A of control −A of osteosarcoma
cells) × 100%.
Invasion assay
Invasion assay was performed using Boyden chambers
with inserts (pore size: 8 μm) coated with Matrigel in
24-well plates. Briefly, osteosarcoma cells (4 × 105 cells/mL)
were suspended in 250 μL medium containing 2% FBS in
the upper chamber, which was pre-coated with 15 μL
Matrigel (0.5 μg/mL). BMSCs were seeded onto the lower
layer of transwells at a density of 2 × 105 cells/well. The
co-culture system was incubated at room temperature for
15 min. The control group consisted of plates with
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upper chamber only. The plates were incubated for 24 h
at 37°C. Cells on the upper side of the filters were re-
moved with cotton-tipped swabs, and invaded cells were
fixed with 4% paraformaldehyde, washed with PBS, air
dried, and stained with crystal violet for 30 min. They
were then rinsed several times with distilled water. The
number of invading cells was counted in five random
microscopic fields.
ELISA assay
After culturing cells for 72 h at 37°C containing 5% CO2
in a humidified incubator, the culture medium was col-
lected separately and centrifuged at 1,000 rpm for 5 min
to remove debris. The supernatants were then frozen at
−80°C for further assessment by ELISA. ELISA was
performed using the human CXCL12/SDF-1 kit (R&D
Systems, Minneapolis, MN, USA) according to the
manufacturer’s instructions.
Reverse transcription polymerase chain reaction
Total RNA was extracted from cultured cells using Trizol
(Invitrogen, Carlsbad, CA, USA). The cDNA was synthe-
sized using a random primer from 1 μg of total RNA with
the Revert Aid First Strand cDNA Synthesis Kit according
the to manufacturer’s instructions (Fermentas, Glen Bur-
nie, MD, USA). The following primers were used for re-
verse transcription polymerase chain reaction (RT-PCR):
human SDF-1 (sense, 5′-gctttgagtgactgggtt-3′; antisense,
5′-gtggcaagatgatggttt-3′), PCR product size: 124 bp; hu-
man CXCR4 (sense, 5′-gaagctgttggctgaaaagg-3′; antisense,
5′-gagtcgatgctgatcccaat-3′), PCR product size: 345 bp;
and human beta-actin (sense, 5′-actcttccagccttccttc-3′;
antisense, 5′-tgtcaccttcaccgttcc-3′), PCR product size:
516 bp. PCR was performed following the manufacturer’s
instructions. The cycling conditions were 3 min at 94°C,
followed by 30 cycles of denaturation at 94°C for 30 s, an-
nealing at 54°C for 30 s, and extension at 72°C for 60 s.
Amplified DNA fragments were resolved by electrophor-
esis on 1% agarose gels containing ethidium bromide.
Statistical analysis
Data were expressed as means ± standard deviation (SD)
and analyzed using analysis of variance (ANOVA). P < 0.05
was considered statistically significant.
Results
Identification of BMSCs
Primary human BMSCs were spindle-shaped and adher-
ent to the dish (Figure 1A). Several BMSC markers were
confirmed by flow cytometric analysis, including CD29,
CD90, and CD45 (97.22 ± 1.94, 94.91 ± 3.88, and 2.22 ±
0.21% positivity, respectively) (Figure 1B). The CD
marker analysis of BMSCs was consistent with typicalmesenchymal stem cells. After differentiation, the accu-
mulated adipocytes in BMSCs were detected by oil red
O staining for the various treatments. Most of the
BMSCs differentiated into adipocytes successfully, and
Oil red O staining detected numerous fat droplets in the
cytoplasm of adipocytes.Effect of BMSCs on the proliferation and invasion of
osteosarcoma cells
Using a cell co-culture system, we found that BMSCs pro-
mote the proliferation of osteosarcoma cells (Figure 2A).
The number of osteosarcoma MG-63 and OS732 cells cul-
tured with BMSCs in the system was significantly higher
than the cells grown in the absence of BMSCs. Moreover,
the invasion of osteosarcoma cells incubated with the
BMSC supernatant was enhanced (Figure 2B).Secretion of SDF-1 by BMSCs
The amounts of SDF-1 secreted by BMSCs and osteosar-
coma cells were determined by ELISA. The concentra-
tion of SDF-1 in the BMSC supernatant was nearly
600 pg/mL. Importantly, a very low concentration of
SDF-1 was detected in the supernatant of osteosarcoma
cells (Figure 3A). These data confirmed that BMSCs, but
not osteosarcoma cell lines, secret SDF-1.Expression of SDF-1 and CXCR4 in cultured osteosarcoma
cell lines and BMSCs
We evaluated the expression of SDF-1 and CXCR4 by
RT-PCR in cultured cells. BMSCs exhibited a higher ex-
pression of SDF-1 compared to MG-63 and OS732 cells
(Figure 3B). However, these two osteosarcoma cell lines
showed a higher expression of CXCR4 compared to
BMSCs (Figure 3C).Effects of SDF-1 on the proliferation of osteosarcoma cell
lines
SDF-1 enhanced the proliferation of osteosarcoma cells in a
dose-dependent manner compared to controls (Figure 4A).
The CXCR4 antagonist AMD3100 significantly blocked
SDF-1-induced proliferation (P < 0.05) but did not inhibit
MG-63 and OS732 basal cell growth in the absence of
SDF-1 (Figure 4B).Effects of BMSCs on the proliferation of osteosarcoma
cells in the presence of AMD3100
The effect of BMSCs on MG-63 and OS732 cell growth
in the presence of AMD3100 was also determined using
the CCK-8 assay. We found that BMSCs enhanced the
proliferation of both osteosarcoma cell lines, which were
significantly reduced by the addition of AMD3100 in a
dose-dependent manner (P < 0.05) (Figure 4C).
Figure 2 Effect of BMSCs on the proliferation and invasion of osteosarcoma cells. (A) After co-culturing BMSCs with osteosarcoma cells for
72 h, the proliferation of osteosarcoma cells was examined using the CCK-8 assay. The proliferation of MG-63 and OS732 cells co-cultured with
BMSCs was significantly increased compared to that of the respective cells cultured alone. (B) BMSCs were co-cultured with osteosarcoma cells
for 72 h, and the percentage of osteosarcoma cell invasion was examined under a microscope. The invasion of MG-63 and OS732 cells was
significantly greater in the presence of BMSCs compared to control cells.
Figure 1 Identification of bone marrow-derived stem cells. (A) The phenotype of BMSCs isolated from human bone marrow tissue (on the
first day; 100× magnification fold). (B) The expression of CD45, CD29, and CD90 in isolated BMSCs. (C) The fat droplets were observed in the
cytoplasm of adipocytes at 400× magnification. (D) The fat droplets were stained with Oil red O. Image is magnified 200 ×.
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Figure 4 Effects of SDF-1 on the proliferation of osteosarcoma cell lines. (A) SDF-1 promotes the proliferation of osteosarcoma cells in a
dose-dependent manner. (B) AMD3100 partially blocks SDF-1-mediated proliferation. (C) AMD3100 downregulates the effects of BMSCs on
osteosarcoma cell line proliferation.
Figure 3 SDF-1 secretion and SDF-1 and CXCR4 expression. (A) The SDF-1 concentration in the BMSC supernatant as detected by ELISA.
BMSCs had significantly higher levels of SDF-1 compared to MG-63 and OS732 cells. (B) The RT-PCR analysis of SDF-1 mRNA expression in
osteosarcoma cell lines and BMSCs. (C) The RT-PCR analysis of CXCR4 mRNA expression in osteosarcoma cell lines and BMSCs. (*P < 0.01
compared to the BMSCs).
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The interaction between the tumor and tumor-associated
stroma has been reported in many studies, and the im-
portance of the local tumor microenvironment for tumor
progression has been recognized for many years [21,22].
This study demonstrated that BMSCs promote osteosar-
coma cell proliferation and invasion in vitro. Furthermore,
we demonstrated that the SDF-1/CXCR4 axis plays an im-
portant role in mediating the tumor-promoting effect.
Since BMSCs are derived from bone marrow tissue
that is abundant in the tissues adjacent to osteosarcoma,
it is very important for their capacity to promote osteo-
sarcoma cell growth. We first found that BMSCs, but
not osteosarcoma cells, secret SDF-1. SDF-1 is a se-
creted chemokine that is released into the interstitial
space, where it acts on cells in the local microenviron-
ment in a paracrine fashion to stimulate directional mi-
gration of hematopoietic and nonhematopoietic normal
and malignant cells [23]. SDF-1 exerts a variety of bio-
logical functions, including the regulation of angiogen-
esis and inhibition of apoptosis as well as tumor growth,
migration, and invasion promoting effects through the
SDF-1/CXCR4 receptor ligand axis [24-26]. Further-
more, Brand et al. demonstrated that SDF-1 stimulation
induces a significant increase in VEGF protein levels in
the colorectal cancer line HT-29 [27]. SDF-1 has also
been demonstrated to play a role in tumors, including
breast cancer, melanoma, ovarian cancer, gastric cancer,
and other carcinomas [12].
We also assessed the expression of CXCR4 in the two
osteosarcoma cell lines using RT-PCR and found that
the mRNA levels were elevated compared to controls. In
contrast, CXCR4 mRNA levels were very low in BMSCs.
Importantly, these results were consistent with previous
studies [13,28]. We also found that the SDF-1/CXCR4
axis plays an important role in the proliferation of osteo-
sarcoma cells. In this study, we demonstrated that recom-
binant SDF-1 could significantly promote the proliferation
of osteosarcoma cells. Blocking the receptor with
AMD3100 was sufficient for preventing SDF-1-mediated
proliferation in MG-63 and OS732 cells. It has been fur-
ther reported that CXCR4 signaling in osteosarcoma cell
lines can promote MG-63 and OS732 proliferation [29].
Taken together, therefore, these data suggest that CXCR4
is a potential therapeutic target in osteosarcoma.
Moreover, we found that BMSCs stimulate the invasive
behavior of osteosarcoma cells. An invasion assay using
a Matrigel-coated invasion chamber showed that BMSCs
stimulated invasion of osteosarcoma cells and that these
effects were inhibited by the addition of the CXCR4 in-
hibitor AMD3100. Therefore, SDF-1 plays a critical role
in promoting the invasion of osteosarcoma cells. However,
although the BMSC-induced proliferation was inhib-
ited by AMD3100, proliferation was still higher thanthe control. Therefore, other factors, such as matrix
metalloproteinase-9 (MMP-9), MMP-2, and vascular
endothelial growth factor [10,30], may also be involved
in promoting the proliferation and invasion of osteo-
sarcoma cells. It has been shown that myofibroblast-
derived SDF-1 recruits endothelial progenitor cells to
sites of carcinomas, thereby enhancing angiogenesis
and tumor growth [31]. Therefore, BMSC-derived SDF-1
may be partially responsible for the proliferation and inva-
sion of osteosarcoma cells.
Conclusions
The aim of this study was to gain a better understand of
the mechanisms related to osteosarcoma growth and in-
vasion. Despite advances in surgical and medical therap-
ies, overall survival rate for patients with osteosarcoma
remains low [32,33]. Therefore, a better understanding
of the fundamental nature of this cancer is needed to
improve clinical outcome. Our finding that local stem
cells adjacent to osteosarcoma cells are involved in
tumor growth and invasion may be useful for osteosar-
coma therapy, as these results suggest that the bone
marrow tissue surrounding the osteosarcoma tissue
should be resected completely. Future studies need to
confirm these findings.
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